With respect to South Korea, Novartis solved specified properly-publicized allegations that it had made incorrect payments to HCPs in South Korea by means of spherical tables and third-occasion medical journals. Novartis Korea allegedly transmitted improper honoraria to HCPs for round tables via health-related journals to stop compliance scrutiny,